DUBLIN--(BUSINESS WIRE)--The "Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III and Unknown stages are 2, 1, 1 and 1 respectively.
Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Report Coverage
- Microscopic Polyangiitis (MPA) - Overview
- Microscopic Polyangiitis (MPA) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Microscopic Polyangiitis (MPA) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
- Celltrion Inc
- ChemoCentryx Inc
- Sandoz International GmbH
- Teijin Pharma Ltd
- TTY Biopharm Company Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5wcscc/microscopic?w=4
